Follicle-stimulating hormone receptor (FSHR) a promising novel target for cancer diagnosis in seminoma and embryonal carcinoma by Malivindi, Rocco et al.
IJAE 
Vo l .  122 ,  n .  1  (Supp lem ent) :  128 ,  2017
© 2017 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
Follicle-stimulating hormone receptor (FSHR) a 
promising novel target for cancer diagnosis in 
seminoma and embryonal carcinoma
Rocco Malivindi1, Daniela De Rose1,2*, Marta Santoro, Serena Gervasi3, Vittoria Rago1# and Saveria 
Aquila1,2#
1 Department of Pharmacy and Sciences of Health and Nutrition, University of Calabria, Rende (CS); 
2 Centro Sanitario, University of Calabria, Rende (CS). 
3 University ‘Magna Graecia’ Catanzaro, (CZ) Italy.
* Equally contributed to this study.
 # Joint senior authors.
Adult testicular germ cell tumors (TGCTs) are the most frequent malignant tumors 
in male patients aged 15–45 years, their incidence is increasing in recent years. There are 
two main subclasses of TGCTs: seminomas (SE) and non-seminomatous germ cell tumors 
(NSGCTs). SE have histological features of primordial germ cells, whereas NSGCTs have 
varying degrees of differentiation (i.e. embryonal carcinoma, EC), they present distinctive 
clinical features and differ for therapy and prognosis. NSGCTs tend to be metastatic at 
presentation, and have a worse prognosis than seminomas at an equivalent stage of dis-
ease. Despite general advances in the management of TGCTs, the molecular bases under-
lying their progression remain almost unknown. The effects of the Follicle-stimulating 
hormone (FSH), central hormone in mammalian reproductive biology, are mediated by 
FSHR, which was believed to be expressed primarily in ovary and testis. Recently, FSHR 
expression has been shown in the blood vessels of different solid tumors, including pros-
tate, urothelial and breast carcinomas, suggesting a role in neoangiogenesis. The expres-
sion of FSHR at the periphery of tumors, also suggests that FSHR may be of relevance to 
the metastatic process. In normal human testis, estrogen physiological actions are medi-
ated by estrogen receptor (ER) β and highly variable ERβ expression has been reported in 
the different TGCTs. ERβ loss is associated with advanced tumor stage in several cancers 
and previously, we showed a higher expression of ERβ1 in SE with respect EC. In this 
study, we evaluated the expression of FSHR in normal and neoplastic human testis tis-
sues. Further, we compared FSHR expression with that of ERβ1 in the same samples. In 
normal testes, immunohistochemical studies showed the presence of FSHR prevalently in 
somatic testicular cells, while ERβ1 is expressed both in somatic and germinal testicular 
cells. Intriguingly, we discovered that FSHR was strongly expressed in EC and absent in 
SE. Conversely, immunostaining for ERβ1 revealed higher intensity in SE as compared to 
EC. These data suggest distinct physiopathological roles for the two receptors in TGCTs 
progression, being ERβ1 protective and FSHR harmful. Our data report for the first time 
the expression of FSHR in TGCTs, suggesting its possible involvement in testicular car-
cinogenesis. FSHR may be considered an useful molecular marker to distinguish semi-
noma from embryonal carcinoma, the most common TGCTs subtypes, and this could be 
informative in clinical decision making and patient counseling.
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